Source: International Congress 2018 – Asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Sanchez-Carpintero Abad (Madrid, Spain), V. Collados Arroyo (Madrid, Spain), G. Doblaré Higueras (Madrid, Spain), A. Henriquez Santana (Madrid, Spain), F. Ruiz Hornillos (Madrid, Spain), S. Blanco Bermejo (Madrid, Spain), F. Roig Vazquez (Madrid, Spain). When omalizumab is effective, should treatment be for life?. 1697

Member's Comments

No comment yet.

Related content which might interest you: Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 What patients with IPF can expect concerning symptoms and quality of life during first six months of antifibrotic treatment? Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Long term efficacy and safety of omalizumab in patients with allergic asthma-A real life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Inhaled corticosteroids - widely prescribed in early life despite little data on safety and efficacy Source: Eur Respir J 2001; 18: Suppl. 33, 523s Year: 2001 The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 Achieving guideline-based asthma control: does the patient benefit? Source: Eur Respir J 2002; 20: 588-596 Year: 2002 How does patient‘s quality of life guide their preferences regarding asthma therapy? Source: Annual Congress 2006 - Respiratory disease managment in primary care Year: 2006 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Does combination therapy lead to better adherence in asthma? Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where? Source: Eur Respir J 2011; 38: 947-958 Year: 2011 Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease Source: Eur Respir J 2003 Dec 01;22(6):912-919 Year: 2003 Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Omalizumab in severe asthma: real life study Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Adjustable maintenance treatment with budesonide/formoterol combination rapidly improves and maintains quality of life in asthma patients Source: Eur Respir J 2002; 20: Suppl. 38, 41s Year: 2002